ReviewJournal of clinical medicine2017
IL-23 and Th17 Disease in Inflammatory Arthritis.
Review in Journal of clinical medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 63 citations in OpenAlex.
- Low-Dose Sirolimus Immunoregulation Therapy in Patients with Active Rheumatoid Arthritis: A 24-Week Follow-Up of the Randomized, Open-Label, Parallel-Controlled Trial.Journal of immunology research · 2019Trial
- Computational identification and experimental validation of shared diagnostic biomarkers and gene signatures across HLA-B27-associated immune-mediated diseases.Journal of translational medicine · 2026Article
- Review
- Divergent roles of IL-35 and IL-39 in rheumatoid arthritis: restoring cytokine balance within the IL-12 family.Frontiers in immunology · 2026Review
- Genetic and Functional Characterization of STAT4 in Rheumatoid Arthritis Patients with Distinct Disease Activity.International journal of molecular sciences · 2025Article
- Tildrakizumab as a Potential Option for Early Psoriatic Arthritis in Patients with Metabolic Comorbidities and Psoriasis: a Case Series.Dermatology practical & conceptual · 2025Article
- Therapeutic potentials of Trichinella spiralis in immune disorders: From allergy to autoimmunity.Parasites, hosts and diseases · 2025Review
- MiR-223 within neutrophil axis promotes Th17 expansion by PI3K-AKT pathway in systemic lupus erythematosus.Arthritis research & therapy · 2025Article
- IL-23R is a senescence-linked circulating and tissue biomarker of aging.Nature aging · 2025Article
- Severe fatigue is associated with diminished lung function and elevated Galectin-9 levels in early systemic sclerosis.Frontiers in immunology · 2025Article
- Effect of Whole-Body Electrical Muscle Stimulation Training on Inflammatory and Anti-inflammatory Cytokines in Overweight Men.Journal of obesity & metabolic syndrome · 2024Article
- Article
- Phenotypic heterogeneity in psoriatic arthritis: towards tissue pathology-based therapy.Nature reviews. Rheumatology · 2023Review
- Genetic Background and Molecular Mechanisms of Juvenile Idiopathic Arthritis.International journal of molecular sciences · 2023Review
- Iridoid fromEvidence-based complementary and alternative medicine : eCAM · 2023Article
- Significance of Interleukin 23 in Systemic Lupus Patients: Relation to Disease Activity and Damage Indices.Biologics : targets & therapy · 2023Article
- Pipeline Impact of Radiolabeled Compounds in Drug Discovery and Development.ACS medicinal chemistry letters · 2022Review
- Review
- Inflammation and Bone Metabolism in Rheumatoid Arthritis: Molecular Mechanisms of Joint Destruction and Pharmacological Treatments.International journal of molecular sciences · 2022Review
- Ezetimibe ameliorates clinical symptoms in a mouse model of ankylosing spondylitis associated with suppression of Th17 differentiation.Frontiers in immunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
IL-23, which is composed of p19 and p40 subunits, is a proinflammatory cytokine that contributes to the formation and maintenance of Th17 cells in inflammatory autoimmune diseases. IL-23 is a human osteoclastogenic cytokine and anti-IL-23 antibody attenuates paw volume and joint destruction in CIA rats. IL-23 levels in serum and synovial fluid are high in rheumatoid arthritis (RA) patients, and IL-23 may be a useful biomarker for the diagnosis of RA. In addition, IL-23 affects the pathogenesis of inflammation and bone destruction through interaction with other cytokines such as IL-17 and TNF-α. Furthermore, polymorphisms of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.